NCT04700163View on ClinicalTrials.gov

RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

C144-LS and C-135-LS

A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein

Trial Locations (1)

10065

The Rockefeller University, New York

All Listed Sponsors
lead

Rockefeller University

OTHER

NCT04700163 - RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers | Biotech Hunter | Biotech Hunter